EU/3/01/060: Orphan designation for the treatment of malignant mesothelioma

pemetrexed disodium

Table of contents


Please note that this product was withdrawn from the Community Register of designated Orphan Medicinal Products in June 2004 on request from the sponsor.

On 17 September 2001, orphan designation (EU/3/01/060) was granted by the European Commission to Eli Lilly Nederland B.V, Netherlands, for pemetrexed disodium for the treatment of malignant mesothelioma.

Key facts

Active substance
pemetrexed disodium
Intended use
Treatment of malignant mesothelioma
Orphan designation status
EU designation number
Date of designation
Eli Lilly Nederland B.V.
Grootslag 1-5
NL-3991 Houten
The Netherlands
Telephone: + 31 30 60 25 800

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating